Physician profile
Jonathan E Holtz
NPI 1104151174
$3,234.85
in general payments reported to CMS, 2019-2025
17 companies · $1,063 in 2025
The $1,063 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.77 · 2020: $216 · 2022: $75.54 · 2023: $486 · 2024: $1,328 · 2025: $1,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,877.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $724.61 | 2022-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $458.27 | 2022-2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $335.95 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Abbott Laboratories | $306.94 | 2019-2025 | Cardiomems |
| Novartis Pharmaceuticals Corporation | $293.97 | 2024-2025 | |
| Boston Scientific Corporation | $223.78 | 2023-2025 | Emblem Mri S-Icd, Lux-Dx Insertable Cardiac Monitor, S-Icd System Magnet |
| Impulse Dynamics (USA) INC. | $214.01 | 2023-2024 | Optimizer, Optimizer |
| Kestra Medical Technology Services, INC. | $136.30 | 2023-2024 | Assure Wcd |
| Scpharmaceuticals INC. | $123.18 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $104.92 | 2023-2025 | Camzyos, Eliquis |
| Johnson & Johnson Health Care Systems INC. | $88.32 | 2024-2025 | Uptravi, Opsumit, Spotlight |
| United Therapeutics Corporation | $55.67 | 2023-2025 | Tyvaso, Tyvaso |
| Janssen Pharmaceuticals, INC | $54.87 | 2024 | Xarelto |
| Cerus Corporation | $39.95 | 2024 | Intercept Blood System For Platelets |
| Astrazeneca Pharmaceuticals Lp | $32.85 | 2024 | Farxiga, Brilinta |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiva Medical, INC. | $25.01 | 2024 | Cardiva Vascade 6/7f Vcs |
| Merck Sharp & Dohme LLC | $16.25 | 2024 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Holtz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.